Slide Show Presentation

October 5, 2006

Investor Presentation

Overview of InfuSystem

Acquisition

HAPC, Inc.

Exhibit 99.1

Disclosure

The attached presentation was filed with the Securities and Exchange Commission (“SEC”) as part of the Form 8–K

filed by HAPC, Inc. (“HAPC”) on October 5, 2006. HAPC is holding presentations for its stockholders regarding its

purchase of InfuSystem, Inc. (“InfuSystem”). A copy of the complete presentation is available at the SEC’s website

(http://www.sec.gov). This presentation has been prepared solely by HAPC. Neither

InfuSystem

nor its affiliates

(including its parent, I-Flow Corporation) have approved or are responsible for the presentation information.

HAPC and its directors, executive officers, affiliates may be deemed to be participants in the solicitation of proxies for

the special meeting of HAPC’s stockholders to be held to approve this transaction. Stockholders of HAPC and other

interested persons are advised to read, when available, HAPC’s proxy statement in connection with HAPC’s

solicitation of proxies for the special meeting to approve the acquisition because this proxy statement will contain

important information. Such persons can also read HAPC’s final prospectus, dated April 11, 2006, as well as periodic

reports filed with the SEC, for more information about HAPC, its

officers and directors, and their interests in the

successful consummation of this business combination. Information about the directors and officers of InfuSystem

as well as updated information about the directors and officers of HAPC will be included in the definitive proxy

statement. The directors and officers of HAPC have interests in the merger, some of which may differ from, or may

be in addition to those of the respective stockholders of HAPC generally. The definitive proxy statement will be

mailed to stockholders as of a record date to be established for

the purpose of convening a special meeting to vote

on this transaction. Stockholders and other interested persons will also be able to obtain a copy of the definitive

proxy statement, the final prospectus and other periodic reports

filed with the SEC, without charge, by visiting the

SEC’s Internet site at (http://www.sec.gov).

Safe harbor

This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of

1995, about HAPC, InfuSystem and their combined business after completion of the proposed transaction. Forward-looking

statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and

expectations of HAPC’s management, are subject to risks and uncertainties, which could cause actual results to differ from

the forward–looking statements. The following factors, among others, could cause actual results to differ from those set

forth in the forward–looking statements: continuous infusion treatment protocol trends, including factors affecting supply

and demand; labor and personnel relations; healthcare payor reimbursement risks affecting HAPC’s revenue and

profitability; conditions in financial markets that impact HAPC’s ability to obtain capital to finance capital expenditures;

changing interpretations of generally accepted accounting principles; and general economic conditions, as well as other

relevant risks detailed in HAPC’s filings with the SEC, including the final prospectus relating to HAPC’s IPO dated April 11,

2006. The information set forth herein should be read in light of such risks. HAPC assumes any obligation to update no

obligationinformation

contained in this presentation.

This presentation contains disclosures of EBITDA for certain periods, which may be deemed to be non–GAAP financial measures

within the meaning of Regulation G promulgated by the SEC. Management of HAPC believes that EBITDA, or earnings before

interest, taxes, depreciation and amortization are appropriate measures of evaluating operating performance and liquidity,

because they reflect the resources available for strategic opportunities including, among others, investments in the business

and strategic acquisitions. The disclosure of EBITDA may not be comparable to similarly titled measures reported by other

companies. EBITDA should be considered in addition to, and not as a substitute for, or superior to, operating income, cash

flows, revenue, or other measures of financial performance prepared in accordance with generally accepted accounting

principles. A reconciliation of EBITDA to net income is included as Annex 1 to this presentation.

Acquisition details

Buyer:

HAPC, Inc. (OTCBB: HAPN)

Target:

InfuSystem, Inc., a leading provider of ambulatory pumps and services to

medical oncologists in the United States.

Seller:

I-Flow Corporation (NASDAQ: IFLO)

Consideration:

$140 million (subject to certain working capital adjustments as

set forth

in the Stock Purchase Agreement)

Anticipated closing:

by the end of 2006 or early 2007

The purchase price will be paid by HAPC in cash or a combination of (i) a secured promissory note (the “Promissory Note”) payable to I-Flow in a principal amount equal to $55

million plus the amount actually paid to HAPC’s stockholders who exercise their conversion rights but not to exceed $75 million (the “Maximum Amount”) and (ii) an amount of

cash purchase price equal to $65 million plus the difference between the Maximum Amount and the actual principal amount of the Promissory Note.

Key facts

leading,

independent

provider

ambulatory

infusion

pumps

and

services

oncologists

and

cancer patients; primarily focused on treatment of colorectal cancers

Headquartered in Madison Heights, MI (near Detroit)

Approximately 111 employees

Strong Financial Performance

$29 million of revenue in 2005

47% revenue growth over 2004

46% EBITDA margins for the six months ended June 2006

See the reconciliation of EBITDA to net income included as Annex 1

As discussed in the following slides

Investment highlights

Leader in growing market

Unique business model

Compelling value proposition

Competitive advantages

Strong relationships with physician offices and payors

Opportunity to expand to other cancer treatments

Strong growth and profit margins

Leader in growing market

148,610 estimated new cases of colorectal cancer (“CRC”) in the U.S. in 2006

Continuous infusion regimens are achieving increased acceptance and are becoming a

market standard chemotherapy for CRC

Introduction of CRC treatment protocols FOLFOX (Sanofi) and FOLFIRI (Pfizer) in

2004

American Cancer Society

Representative growth of continuous infusion

Source: Arrowhead Publishers, 2006

$200

$400

$600

$800

$1,000

$1,200

$1,400

$1,600

$1,800

$2,000

2000

2001

2002

2003

2004

2005

Increasing usage of FOLFOX protocol

Sales of Eloxatin

(Oxaliplatin)

utilized in FOLFOX protocol with 5-FU and leucovorin

$130

$194

$368

$932

$1,517

$1,750

$ in millions

Compelling value proposition

Physicians

Patients

Payors

Professional service fees

Better patient outcomes

Continues relationship with

patient

Less administrative demands

Lower costs

Better patient

outcomes

Continuity of care

Reduces side effects

Comfort and convenience

Lower cost

Competitive Advantages

Regional DME Providers

No significant scale

Limited pump selection

Limited insurance

contracts

Hospital

Other hospitals unlikely

to support competing

hospitals

Limited capital budgets

Home care

Takes revenue from

physician office

More costly for patients

and payors

Less convenient for

patients

Physician owned DME

More time intensive and

costly for physicians

Biomed

On-call

InfuSystem is a leading national provider

of ambulatory infusion pump services for

the oncology specialty

Services approximately 60% of oncology

physician offices and hospital infusion

centers

Strong relationships with physician offices and payors

Relationships with approximately 60% of oncology practices

Opportunity to penetrate deeper within practices (more doctors) and expand

product offerings

Contracts covering approximately 65% of managed care “lives”

Include Aetna, PacifiCare, Humana and others

Expansion opportunities

Continuous infusion therapies may be extended to other cancers

Liver cancer and Hodgkins disease are growing parts of InfuSystem’s business

Drugs approved for lung, gastric, breast, leukemia, non-Hodgkins lymphoma, and

other cancers

Several new drugs in development

Potential distribution of other products through established medical

oncologist relationships

$2.0

$4.0

$6.0

$8.0

$10.0

$12.0

$14.0

$16.0

2003

2004

2005

June 06 YTD

0.0%

10.0%

20.0%

30.0%

40.0%

50.0%

60.0%

$5.0

$10.0

$15.0

$20.0

$25.0

$30.0

2003

2004

2005

June 06 YTD

Strong growth and profit

$1.0

$2.0

$3.0

$4.0

$5.0

$6.0

2003

2004

2005

June 06 YTD

0.0%

2.0%

4.0%

6.0%

8.0%

10.0

12.0

14.0

16.0

18.0

20.0

Revenue

EBITDA

1,2

Margin %

US $ in millions

Calculation of EBITDA excludes stock-based compensation expense of $1.1 million, $0.3 million and $0.1 million in 2005, 2004 and 2003, respectively. Calculation of EBITDA also excludes processing costs borne by InfuSystem for certain

billing and administrative services provided to I-Flow related to I-Flow’s pain management system. Estimates of these costs reflected in InfuSystem’s expenses were $1.2 million, $0.3 million and $0.2 million for 2005, 2004 and 2003,

respectively. See the reconciliation of EBITDA to net income included in Annex 1.

$13.0

$19.3

$28.5

$15.7

$3.4

$7.1

$13.6

$7.2

$1.1

$2.9

$5.1

$2.9

26%

37%

48%

46%

15%

18%

General and administrative expenses do not include overhead costs associated with administrative services and corporate oversight that have historically been provided by I-Flow Corporation, Infusystem’s

parent, at no charge to Infusystem.

Upon acquisition of Infusytem

by HAPC, Inc., these services will no longer be provided by I-Flow Corporation and general and administrative expenses to the Company may increase accordingly.

Net Income²

Annex 1: EBITDA reconciliation

parent, at no charge to InfuSystem.

Upon acquisition of InfuSystem

by HAPC, Inc., these services will no longer be provided by I-Flow Corporation and general and administrative expenses to the Company may increase accordingly.

$’s in millions

2003

2004

2005

June 06

YTD

Net Income

1.1

2.9

5.1

2.9

Plus

Income Tax Provision

0.7

1.7

2.9

1.6

Plus

Interest Expense

0.0

0.1

Plus

Stock Based Compensation Expense

0.1

0.3

1.1

0.1

Plus

ON-Q Processing Costs

0.2

0.3

1.2

0.7

Plus

Depreciation and Amortization

1.3

1.8

3.3

1.8

EBITDA

3.4

7.1

13.6

7.2